Sanofi is constructing a state-of-the-art vaccine manufacturing facility called the Evolutive Vaccine Facility (EVF) in Singapore, aimed at enhancing pandemic preparedness. This facility, in collaboration with the Singapore Economic Development Board, will primarily serve the Asian market and is part of a broader €900 million investment to establish two EVFs globally, with the other in France.

The groundbreaking ceremony took place in April 2022, and operations are expected to start by the end of 2025. The project involves an investment of S$638 million (approximately $466.9 million) and will create around 200 jobs, positioning Singapore as a regional healthcare innovation hub.

The EVF will be a fully digital, modular facility capable of producing multiple vaccine types, including mRNA, enzymes, and monoclonal antibodies, while being designed to be carbon neutral. It will feature advanced technologies for rapid production transitions, taking only 12 days to switch between vaccine types. Sustainable practices will include solar energy usage and reduced resource consumption.

Additionally, the facility will utilize Dassault Systèmes' 3DEXPERIENCE platform for enhanced production flexibility and efficiency. Sanofi is also engaged in developing various vaccine types and therapies across multiple medical fields.